Get regular updates to your inbox.
The Phase 3 ADVOCATE trial, evaluating ChemoCentryx‘s investigational drug avacopan (formerly CCX168) for the treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis is now enrolling participants. The update is part of the company’s financial report for the second quarter of 2017. The study (NCT02994927), which aims to evaluate the safety…
People with anti-neutrophil cytoplasmic antibodies (ANCA)-associated vasculitis have a lesser chance of relapse if they continue with maintenance treatment for two years instead of one, according to the results of a clinical trial. The trial, led by researchers at the Hôpital Européen Georges-Pompidou in France, also showed that patients…
HemaCare Corporation‘s recent expansion of its disease state materials portfolio includes serums from rare diseases such as granulomatosis with polyangiitis (GPA). The Los Angeles-based supplier of human blood and immune cells for biotech research added to the portfolio in response to increased demand from its customers in the drug…
Physicians, specialists, patients and families touched by vasculitis nationwide and around the world gathered June 23 at the Vasculitis Foundation’s 2017 International Vasculitis Symposium in Chicago. “Physicians and patients around the world have been looking to us for education and support for…
The European Commission (EC) has approved the use and marketing in Europe of Rixathon, a biosimilar to Roche’s MabThera (rituximab). The decision follows a positive review of Rixathon by the Committee for Medicinal Products for Human Use (CHMP) last April in response to Sandoz’s marketing application.
Nucala (mepolizumab) effectively induced remission in about half of patients with eosinophilic granulomatosis with polyangiitis (EGPA) that relapsed or did not respond to treatment, according to results from a Phase 3 clinical trial (NCT02020889). The study found that Nucala reduced…
Get regular updates to your inbox.